We are excited to join Nucleate New York at their 5th Anniversary celebration on July 10th. This event will highlight their five years of accomplishments within the New York life science ecosystem and their plans to create even more impact moving forward. Join us for this fantastic opportunity to network with the next generation of biotech talents who are defining the future of the industry.
What is Nucleate New York
Nucleate New York is a 501(c)(3) nonprofit organization dedicated to supporting and guiding early-career bioinnovators. They are one of the most active hubs out of the 32 chapters that make up the global Nucleate network. Through programs such as the Activator and PATH, they help provide useful resources and remove entry barriers to biotech entrepreneurship.
Event Overview
Date: July 10th, 2026
Venue: West End Labs, 125 WEst End Ave., New York, NY 10023
Event Schedule
For more information, please refer to the Nucleate website.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
